After a decade of intravesical vanilloid therapy: Still more questions than answers

Lancet Neurology

Volumn 1, Issue 3, 2002, Pages 167-172

  Szallasi, Arpad ^a   Fowler, Clare J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ARVANIL; CAPSAICIN; OLVANIL; RESINIFERATOXIN; VANILLOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; UNSATURATED FATTY ACID;

BLADDER EMPTYING; CLINICAL TRIAL; DESENSITIZATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE CONTROL; GENE EXPRESSION; GENE TECHNOLOGY; HUMAN; IMMUNOREACTIVITY; INNERVATION; MICTURITION DISORDER; MICTURITION REFLEX; MULTIPLE SCLEROSIS; NONHUMAN; PONS; PRIORITY JOURNAL; REVIEW; SPINE INJURY; URINE VOLUME; ANIMAL; BLADDER DISEASE; CHEMISTRY; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CAPSAICIN; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HUMANS; RECEPTORS, DRUG; URINARY BLADDER DISEASES;

EID: 0000713128     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00072-8     Document Type: Review

References (63)

1. Wood J.N. Capsaicin in the study of pain. 1993;Academic Press, San Diego, CA.
2. Szallasi A. Vanilloid-sensitive neurons: a fundamental subdivision of the peripheral nervous system. J Peripher Nerv Syst. 1:1996;6-18.
3. Szallasi A., Blumberg P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 51:1999;159-211.
4. Winter J., Bevan S., Campbell E.A. Capsaicin and pain mechanisms. Br J Anesth. 75:1995;157-168.
5. Robbins W. Clinical applications of capsaicinoids. Clin J Pain. 16:2000;S86-89.
6. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:1997;816-824.
7. Cruz F. Desensitisation of bladder sensory fibres by intravesical capsaicin or capsaicin analogs: a new strategy for treatment of urge incontinence in patients with spinal detrusor hyperreflexia or bladder hypersensitivity disorders. Int Urogynecol J. 9:1998;214-229.
8. Chancellor M.B., de Groat W.C. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways we treat the overactive bladder. J Urol. 162:1999;3-11.
9. Kim D.Y., Chancellor M.B. Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol. 14:2000;97-103.
10. De Ridder D., Baert L. Vanilloids and the overactive bladder. BJU Int. 86:2000;172-180.
11. Fowler C.J. Intravesical treatment of overactive bladder. Urology. 55:(suppl 1):2000;60-64.
12. Appendino G., Szallasi A. Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci. 60:1997;681-696.
13. Sterner O., Szallasi A. Novel natural vanilloid receptor agonists: new therapeutic targets for drug development. Trends Pharmacol Sci. 20:1999;431-439.
14. Brand L., Berman E., Schwen R., et al. NE-19550: a novel, orally active anti-inflammatory analgesic. Drugs Exp Clin Res. 13:1987;259-265.
15. Cruz F., Guimarães M., Silva C., Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet. 350:1997;640-641.
16. Szallasi A., Blumberg P.M. Resiniferatoxin. Conn P.M. Methods in neurosciences, vol 8. Neurotoxins. 1992;368-380 Academic Press, San Diego, CA.
17. Di Marzo V., Bisogno T., de Petrocellis L. Anandamide: some like it hot. Trends Pharmacol Sci. 22:2001;346-349.
18. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
19. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
20. Szolcsányi J. Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci. 21:2000;41-42.
21. Zygmunt P.M., Julius D., di Marzo V., Högestätt E.D. Anandamide-the other side of the coin. Trends Pharmacol Sci. 21:2000;43-44.
22. Szallasi A., di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci. 23:2000;491-497.
23. Di Marzo V., Breivogel C., Bisogno T., et al. Neurobehavioral activity in mice of n-vanillyl-arachidonyl-amide. Eur J Pharmacol. 406:2000;363-374.
24. Brady C.M., DasGupta R., Wiseman O.J., Dalton C.M., Berkley K.J., Fowler C.J. The effect of cannabis based medicinal extract on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. J Neurol Neurosurg Psychiatry. 72:2002;133-142.
25. Bisogno T., Hanus L., De Petrocellis L., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 134:2001;845-852.
26. Tominaga M., Julius D. Capsaicin receptor in the pain pathway. Jpn J Pharmacol. 83:2000;20-24.
27. García-Martínez C., Morenilla-Palao C., Planells-Cases R., Merino J.M., Ferrer-Montiel A. Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties. J Biol Chem. 275:2000;32552-32558.
28. Montell C., Birnbaumer L., Flockerzi V., et al. A unified nomenclature for the superfamily of TRP cation channels. Mol Cell. 9:2002;229-231.
29. Hayes P., Meadows J.H., Gunthorpe M.J., et al. Cloning and expression of a human orthologue of rat vanilloid receptor-1. Pain. 88:2000;205-215.
30. Touchman J.W., Anikster Y., Dietrich N.L., et al. The genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome Res. 10:2000;165-173.
31. Tominaga M., Caterina M.J., Malmberg A.B., et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 21:1998;531-543.
32. Jordt S.E., Tominaga M., Julius D. Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci USA. 97:2000;8134-8139.
33. Jordt S.E., Julius D. Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell. 108:2002;421-430.
34. Premkumar L.S., Ahern G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature. 408:2000;985-990.
35. Vellani V., Mapplebeck S., Moriondo A., Davis J.B., McNaughton P.A. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat, and anandamide. J Physiol. 534:2001;813-825.
36. De Petrocellis L., Harrison S., Bisogno T., et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem. 77:2001;1660-1663.
37. Chuang H.H., Prescott E.D., Kong H., et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature. 411:2001;957-962.
38. Suzuki M., Sato J., Kutsuwada K., Oaki G., Imai M. Cloning of a stretch-inhibitable nonselective cation channel. J Biol Chem. 274:1999;6330-6335.
39. Xue Q., Yu Y., Trilk S.L., Jong B.E., Schumacher M.A. The genomic organisation of the gene encoding the vanilloid receptor: evidence for multiple splice variants. Genomics. 76:2001;14-20.
40. Cruz F., Avelino A., Cruz C., Nagy I. Sensory fibres immunoreactive to the vanilloid receptor protein: distribution in the rat urinary bladder. Neurourol Urodyn. 19:2000;456-467.
41. 3 purinoceptor and IB4 binding sites. Eur J Neurosci. 11:1999;946-958.
42. Avelino A., Cruz C., Nagy I., Cruz F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience. 109:2002;787-798.
43. 3 in human urinary bladder. BJU Int. 87:2001;774-779.
44. Cockayne D.A., Hamilton S.G., Zhu Q.M., et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 407:2000;1011-1015.
45. Caterina M.J., Leffler A., Malmberg A.B., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 288:2000;306-313.
46. Davis J.B., Gray J., Gunthorpe M.J., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature. 405:2000;183-187.
47. de Groat W.C., Kawatani M., Hisamitsu T., et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst. 30:1990;S71-77.
48. de Groat W.D. A neurologic basis for the overactive bladder. Urology. 50:(suppl 6A):1997;36-52.
49. Fowler C.J., Jewkes D., McDonald W.I., Lynn B., deGroat W.C. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet. 339:1992;1239.
50. Birder L.A., Kanai A.J., de Groat W.C., et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA. 98:2001;13396-13401.
51. Kim J.C., Beckel J.M., Birder L.A., et al. Identification of functional vanilloid receptors in human bladder urothelial cells using a nitric oxide microsensor technique and reverse transcriptase polymerase chain reaction. J Urol. 165:(suppl 5):2001;34.
52. De Petrocellis L., Bisogno T., Maccarrone M., Davis J.B., Finazzi-Agro A., Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem. 276:2001;12856-13863.
53. Goso C., Piovacari G., Szallasi A. Resiniferatoxin-induced loss of vanilloid receptors is reversible in the urinary bladder but not in the spinal cord of the rat. Neurosci Lett. 162:1993;197-200.
54. Avelino A., Cruz F. Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibres after topical desensitisation by capsaicin and resiniferatoxin. Auton Neurosci. 86:2000;37-46.
55. Cruz F., Avelino A., Coimbra A. Intravesical vanilloid application increases galanin and c-Jun immunoreactivity in rat dorsal root ganglion cells. Soc Neurosci Abstr. 25:1999;1687.
56. Miller M.S., Buck S.H., Sipes I.G., Yamamura H.I., Burks T.F. Regulation of substance P by nerve growth factor: disruption by capsaicin. Brain Res. 250:1982;193-196.
57. Lowe E., Anand P., Terenghi G., Williams-Chestnut R., Sinicropi D., Osborne J. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Pharmacol. 79:1977;572-577.
58. Okragly A.J., Niles A.L., Saban R., et al. Elevated tryptase, nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol. 161:1999;441-442.
59. Chuang Y.C., Fraser M.O., Yu Y., Chancellor M.B., de Groat W.C., Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 165:2001;975-979.
60. Winston J., Toma H., Shenoy M., Pasricha P.J. Nerve growth factor regulates VR1 mRNA levels in cultures of adult dorsal root ganglion neurons. Pain. 89:2001;181-186.
61. Yiangou Y., Facer P., Dyer N.H.C., et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 357:2001;1338-1339.
62. Simone D.A., Nolano M., Johnson T., Wendelschaefer-Crabb G., Kennedy W.R. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibres: correlation with sensory function. J Neurosci. 18:1998;8947-8959.
63. O'Reilly B.A., Kosaka A.H., Knight G.F., Chang T.K., Ford A.P.D.W., Rymer J.M. P2X receptors and their role in female idiopathic detrusor instability. J Urol. 167:2002;157-164.